Electronic comments can be sent directly to EPA at:

opp-docket@epamail.epa.gov

Electronic comments must be submitted as an ASCII file avoiding the use of special characters and any form of encryption.

The official record for this notice, as well as the public version, as described above will be kept in paper form. Accordingly, EPA will transfer all comments received electronically into printed, paper form as they are received and will place the paper copies in the official record which will also include all comments submitted directly in writing. The official record is the paper record maintained at the address in ''ADDRESSES'' at the beginning of this document. Accordingly, interested persons may submit written views on this subject to the Field Operations Division at the address above.

The Agency, accordingly, will review and consider all comments received during the comment period in determining whether to issue the emergency exemption requested by the California Department of Pesticide Regulation.

List of Subjects

Environmental protection, Pesticides and pests, Emergency exemptions.

Dated: February 19, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of Pesticide Programs.

[FR Doc. 97–5198 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[FRL–5699–4]

Agency Information Collection Activities Under OMB Review

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces the Office of Management and Budget's (OMB) responses to Agency clearance requests, in compliance with the Paperwork Reduction Act (44 U.S.C. 3501 *et. seq.*). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations are listed in 40 CFR Part 9 and 48 CFR Chapter 15.

FOR FURTHER INFORMATION CONTACT: Sandy Farmer, (202) 260–2740; please refer to the appropriate EPA Information Collection Request (ICR) Number.

SUPPLEMENTARY INFORMATION:

OMB Responses to Agency Clearance Requests

OMB Approvals

EPA ICR No. 1746.01; NESHAP for Elastomers—40 CFR 63, Subpart U; was approved 02/04/97; OMB No. 2060–0356; expires 02/28/2000.

EPA ICR No. 0613.06; Trade Secret Clearance Justification; was approved 02/06/97; OMB No. 2070–0053; expires 02/28/2000.

EPA ICR No. 1001.06; Polychlorinated Biphenyls (PCBs); Exclusions, Exemptions, and Use Authorizations; was approved 02/19/97; OMB No. 2070–0008; expires 02/28/2000.

EPA ICR No. 1687.03; National Emission Standards for Hazardous Air Pollutants for Aerospace Manufacturing and Rework Operations; was approved 02/19/97; OMB No. 2060–0314; expires 09/30/98.

EPA ICR No. 1587.04; Part 70 Operating Permits Regulations; was approved 02/20/97; OMB No. 2060–0243; expires 02/28/2000.

EPA ICR No. 1415.03; NESHAP for Dry Cleaning Facilities/ Perchloroethylene (PCE)–(63, M) was approved 02/20/97; OMB No. 2060–0234; expires 02/28/2000.

EPA ICR No. 0262.08; RCRA Hazardous Waste Permit Application and Modification, Part A; was approved 09/30/96; OMB No. 2050–0034; expires 10/31/99.

EPA ICR No. 0574.10; Addendum to Existing ICR to Include the Final Rule for Certain Microbial Products of Biotechnology; was approved 02/19/97; OMB No. 2070–0012; expires 02/28/2000.

Extension of Expiration Dates

EPA ICR No. 1665.01; Confidentiality Rules; expiration date was extended from 02/28/97 to 04/30/97.

EPA ICR No. 1759.01; Worker Protection Standard; expiration date was extended from 02/28/97 to 05/31/97.

Dated: February 27, 1997.

Joseph Retzer,

Director, Regulatory Information Division

[FR Doc. 97–5420 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–M

[FRC–5699–7]

Release of Volume 2, Risk Assessment and Risk Management in Regulatory Decision-Making; Commission on Risk Assessment and Risk Management

Pursuant to the Federal Advisory Committee Act, Public Law 92–463, notice is hereby given that the Commission on Risk Assessment and Risk Management, established as an Advisory Committee under Section 303 of the Clean Air Act Amendments of 1990, will release Volume 2, of its two-volume final report, Risk Assessment and Risk Management in Regulatory Decision-Making, on March 7, 1997. Volume 1 was released in a public meeting held on January 29, 1997.

If you wish to receive a copy of the final report, either fax your request to 202–233–9540, mail your request to the Commission on Risk Assessment and Risk Management, 529 14th Street, NW, Room 420, Washington, DC 20045, or obtain via the internet at http://www.riskworld.com. Be sure to indicate your complete mailing address and a phone number where you can be reached. If you have already requested a copy of the draft report, or a copy of Volume 1, it is not necessary to send another request. Everyone who requested a copy earlier will be sent Volume 2.

If you need additional information, please call 202–233–9537. The report will not be available prior to March 7, 1997.

Dated: February 27, 1997.

Gail Charnley,

Executive Director, Commission on Risk Assessment and Risk Management.

[FR Doc. 97–5417 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–M

FEDERAL EMERGENCY MANAGEMENT AGENCY

Open Meeting on Implementation of the Hotel and Motel Fire Safety Act of 1990

AGENCY: Federal Emergency Management Agency (FEMA).

ACTION: Notice of open meeting.

SUMMARY: FEMA announces the following open meeting:

NAME: United States Fire Administration.

DATE OF MEETING: March 12, 1997.

PLACE: Federal Emergency Management Agency, U.S. Fire Administration, Building N, Room 309, 16825 South Seton Avenue, Emmitsburg, MD 21727.

TIME: 9:30 a.m.

PROPOSED AGENDA: Presentation on the Hotel and Motel Fire Safety Act, recent amendments to reporting requirements, successor standards, applicability to the hospitality industry, colleges and universities. Open discussion on these and other related issues.

SUPPLEMENTARY INFORMATION: The meeting will be open to the public with approximately 10 seats available on a first-come, first-served basis. Members of the general public who plan to attend the meeting should contact John Ottoson, U.S. Fire Administration, 16825 South Seton Avenue, Emmitsburg, MD 21727, (301) 447–1272, on or before Monday, March 10, 1997.

Minutes of the meeting will be prepared and will be available for public viewing in the Office of the U.S. Fire Administrator, Federal Emergency Management Agency, 16825 South Seton Avenue, Emmitsburg, MD 21727. Copies of the minutes will be available upon request 30 days after the meeting.

Dated: February 27, 1997.

Donald G. Bathurst,

Deputy Administrator.

[FR Doc. 97–5380 Filed 3–4–97; 8:45 am]

BILLING CODE 6718–08–P

FEDERAL TRADE COMMISSION

[File No. 971–0009]

American Home Products Corporation; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement.

SUMMARY: In settlement of alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, will settle antitrust concerns stemming from the Madison, New Jersey-based company's proposed acquisition of Solvay, S.A.'s animal health business. The complaint accompanying the consent agreement alleges that the proposed $463 million acquisition would give American Home Products a dominant position in the market for canine lyme vaccines, canine corona virus vaccines, and feline leukemia vaccines. The agreement would require, among other things, that American Home Products divest Solvay's U.S. and Canadian rights to the three types of vaccines to the Schering-Plough Corporation or another Commission-approved buyer.

DATES: Comments must be received on or before May 5, 1997.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580.

FOR FURTHER INFORMATION CONTACT: William J. Baer, Federal Trade Commission, H–374, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580. (202) 326–2932; George S. Cary, Federal Trade Commission, H–374, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580. (202) 326–3741; Casey R. Triggs, Federal Trade Commission, S–2308, 6th St. and Pa. Ave., N.W., Washington, D.C. 20580. (202) 326–2804.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46, and Section 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of sixty (60) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the accompanying complaint. An electronic copy of the full text of the consent agreement package can be obtained from the Commission Actions section of the FTC Home Page (for February 25, 1997), on the World Wide Web, at ''http://www.ftc.gov/os/actions/htm.'' A paper copy can be obtained from the FTC Public Reference Room, Room H–130, Sixth Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580, either in person or by calling (202) 326–3627. Public comment is invited. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission (''Commission'') has accepted, subject to final approval, an agreement containing a proposed Consent Order from American Home Products Corporation (''AHP'') under which AHP would divest Solvay S.A.'s (''Solvay''), canine lyme vaccine, canine corona virus combination vaccines and feline leukemia combination vaccines. The agreement is designed to remedy the anticompetitive effects resulting from AHP's acquisition of Solvay's animal health business.

The proposed Consent Order has been placed on the public record for sixty (60) days for reception of comments by interested persons. Comments received during this period will become part of the public record. After sixty (60) days, the Commission will again review the agreement and the comments received and will decide whether it should withdraw from the agreement or make final the agreement's proposed Order.

The proposed complaint alleges that the proposed acquisition, if consummated, would constitute a violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, in the markets for canine lyme vaccine, canine corona virus combination vaccines and feline leukemia combination vaccines.

The canine lyme, canine corona virus combination and feline leukemia combination vaccines are the only effective method to prevent certain companion animal diseases. These vaccines work by exposing the host animal's own immune system to specific antigens for the disease. These antigens in turn stimulate the immune system's production of antibodies, which protect the host animal against future exposure to the disease.

Companion animal vaccine manufacturers sell vaccines such as canine lyme, canine corona virus combination and feline leukemia combination to veterinarians, who then charge consumers when they bring their companion animals in for treatment. Veterinarians rely on competition among the vaccine manufacturers to drive down the cost of services they provide. Where a single vaccine manufacturer controls a large share of a vaccine market, that manufacturer is able to extract higher prices as a result.

AHP's proposed acquisition of Solvay's animal health business would give the combined entity a dominant position in the canine lyme, canine corona virus combination and feline leukemia combination vaccine markets. As a result, the combined entity would have the ability to raise prices in each of these markets. Furthermore, entry into these markets is difficult and time consuming because of lengthy development periods and the need for approvals by the United States Department of Agriculture (''USDA'') and is unlikely to offset the competitive harm that would result from the combination of AHP and Solvay's animal health business.

The proposed consent order requires AHP to divest certain assets to Schering-Plough, Ltd. (''Schering-Plough'') relating to Solvay's canine lyme, canine corona virus combination and feline leukemia combination vaccines including, but not limited to, master seeds and cell stock, know-how, intellectual property and research and development. In addition, AHP is required to assist Schering-Plough in obtaining USDA certification. These